Open main menu

Psychiatrienet β

Haloperidol LA-Risperidone

Revision as of 16:08, 20 February 2025 by Joost (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Haloperidol
long acting
Type Antipsychotic
Group Butyrophenones
links
ATC-code N05AD01
Medscape Haloperidol
PubChem 3559
PubMed Haloperidol
Drugs.com haloperidol
Kompas (Dutch) Haloperidol
Wikipedia Haloperidol
Risperidone
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AX08
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Drugs.com risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone

Switch medication from Haloperidol_LA to Risperidone[6][7][8]

Nietinrijdenbord.png Stop Haloperidol_LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Risperidone
  • t= 0 Start dosing 25% of the target dose on the day you normally would have injected the former depot.
  • t= 1 x T1/2 of depot approx. 50% of target dose
  • t= 2 x T1/2 of depot approx. 75% of target dose
  • t= 3 x T1/2 of depot approx. 100% of target dose
  • See 'more information' for the T1/2 of this depot
Infobord.png More information
  • the T1/2 of haloperidol depot is approximately 21 days.[9]
  1. ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
  2. ↑ 2.0 2.1 2.2 2.3 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives Cite error: Invalid <ref> tag; name "pts" defined multiple times with different content
  3. ↑ 3.0 3.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  4. ↑ 4.0 4.1 KNMP; Informatorium Medicamentorum 2023; Monografie "risperidon" (Dutch)
  5. ↑ Woods SW; Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
  6. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  7. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  8. ↑ A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
  9. ↑ KNMP Kennisbank, informatorium medicamentorum: Haloperidol
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Haloperidol_LA-Risperidone&oldid=10592"